Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review

J Addict Med. 2023 Jul-Aug;17(4):407-417. doi: 10.1097/ADM.0000000000001141. Epub 2023 Feb 3.

Abstract

Objectives: This systematic review aimed to identify published articles that evaluated all phenibut toxicity and withdrawal cases to understand better their clinical presentations and treatments.

Methods: A comprehensive literature search was conducted using Medline (Ovid), Embase (Ovid), and Cochrane Library databases to capture all published cases on the presentations and management of phenibut toxicity or withdrawal.

Results: Sixty-two cases from 36 studies on presentation and management of phenibut toxicity or phenibut withdrawal were identified. Of all subjects, 80.7% were male. The average age was 30.9 years (SD, 13.2 years; range, 0-71 years). A total of 86.8% reported obtaining phenibut online, and 63.2% reported concomitant substance use with other addictive agents; benzodiazepines and alcohol were the most combined drugs. The average length of hospital stay was 5.0 days (n = 25; SD, 5.4 days; range, 1-25 days) for phenibut toxicity and 7.7 days (n = 20; SD, 7.8 days; range, 0-30 days) for phenibut withdrawals. The most common symptoms reported during phenibut toxicity were altered mental status, somnolence, psychosis, and movement disorders. Of the phenibut toxicity cases, 48.7% required intubation. Benzodiazepines and antipsychotics were most used to treat phenibut toxicity. For phenibut withdrawal cases, 95.7% reported daily use. The most common symptoms reported during phenibut withdrawals were anxiety, irritability or agitation, insomnia, and psychosis. Sixteen (69.6%) of phenibut withdrawal cases required multiple medications for treatment. Benzodiazepines, baclofen, atypical antipsychotics, gabapentanoids, and barbiturates were commonly used to treat phenibut withdrawals.

Conclusions: The seriousness of presentations, combined with the assortments of medications used for both syndromes, reflects the potential dangers of phenibut use and the need for systematized treatment protocols.

Publication types

  • Systematic Review

MeSH terms

  • Adult
  • Baclofen
  • Benzodiazepines / adverse effects
  • Female
  • Humans
  • Male
  • Substance Withdrawal Syndrome* / drug therapy
  • Substance-Related Disorders* / drug therapy
  • gamma-Aminobutyric Acid

Substances

  • 4-amino-3-phenylbutyric acid
  • gamma-Aminobutyric Acid
  • Benzodiazepines
  • Baclofen